

# Director/PDMR Shareholding

RNS Number : 84870

Novacyt S.A.

03 June 2020

Novacyt S.A.

("Novacyt" or the "Company")

## Director/PDMR Shareholdings

Paris, France and Camberley, UK - 3 June 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 03 June 2020, the following Director purchased ordinary shares of €1/15 each in the Company (the "Ordinary Shares"):

Director	Title	Number of Ordinary Shares purchased	Price paid per Ordinary Share	Resultant beneficial holding	% of issued share capital*
Dr Andrew Heath	Non-Executive Director	3,161	£3.05	20,000	0.03%

\*Based on an issued share capital of 67,673,567 ordinary shares

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

### 1. Details of the person discharging managerial responsibilities / person closely associated

a) Name Dr Andrew Heath - Non Executive Director

### 2. Reason for the Notification

a) Position/status See 1(a) - classified as a PDMR of the Company

b) Initial notification/ Amendment Initial Notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name Novacyt S.A.
- b) LEI 213800BWAC2BF295EG28
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
- a) Description of the Financial instrument, type of ordinary shares of €1/15 each instrument
- Identification code FR0010397232
- b) Nature of the transaction Acquisition of Ordinary Shares
- 
- c) Price(s) and volume(s)
- | Price | Volume |
|-------|--------|
| £3.05 | 3,161  |
- N/A Single transaction as above
- 
- Aggregated information:
- d) · Aggregated volume
- | Price | Volume |
|-------|--------|
| £3.05 | 3,161  |
- Price
- 
- e) Date of the transaction 03 June 2020
- f) Place of the transaction AIM

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

- End -

#### Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 47

arnaud.decheffontaines@fticonsulting.com

#### About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

END

DSHUPUMPQUPUGPW